Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Selegiline Clear all
Completed Phase 2 Interventional

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1

NCT00218517
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Selegiline hydrochloride, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Not listed Phase 1 Interventional

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

NCT00033072
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline Patch for Treatment of Nicotine Dependence

NCT01330030
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Selegiline, matching placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

NCT00443872
View directory record Official record
Conditions
Parkinson's Disease
Interventions
orally disintegrating selegiline (Zelapar)
Drug
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Eligibility
30 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline for Smoking Cessation - 1

NCT00439413
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Selegiline Transdermal Patch, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
College Park, Maryland • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Selegiline in Outpatient Treatment for Cocaine Dependence - 1

NCT00000336
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

NCT07571824
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Selegiline TDS 6 mg/24 hours, EMSAM® TDS 6 mg/24 hours
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

NCT00532116
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Infusion Laboratory: Protocol 1 - Selegeline - 2

NCT00000337
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
31 Years to 47 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Selegiline in Treatment of Cocaine Dependence - 2

NCT00000188
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1995
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

NCT00002154
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Thioctic acid, Selegiline hydrochloride
Drug
Lead sponsor
The Dana Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

NCT01495195
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 19, 2026, 8:29 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study Assessing EmSam in Bipolar Depression

NCT00535262
View directory record Official record
Conditions
Bipolar Depression
Interventions
EmSam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Not listed Phase 4 Interventional

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

NCT02225548
View directory record Official record
Conditions
Parkinson's Disease, Erectile Dysfunction
Interventions
Selegiline, Tadalafil
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 64 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Pharmacological Modulation of Cocaine Effects - 1

NCT00000201
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Usefulness of Selegiline as an Aid to Quit Smoking - 1

NCT00129311
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Selegiline, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

NCT00013585
View directory record Official record
Conditions
Cognition Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Not applicable Interventional

A Study of Decreased Mental Function Associated With HIV

NCT00027040
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Scottsdale, Arizona • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

NCT00285766
View directory record Official record
Conditions
Major Depression
Interventions
Selegiline Transdermal System
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
15
States / cities
Chula Vista, California • San Diego, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
16
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Selegiline to Zelapar Switch Study in Parkinson Disease Patients

NCT00640159
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Zelapar
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
La Jolla, California • Sunnyvale, California • Boca Raton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 19, 2026, 8:29 AM EDT